STATENS SERUM INSTITUT (SSI)
Center for Vaccine

STATENS SERUM INSTITUT

Monday, 22 May 2017

Allergy, Asthma and adjuvants – new concepts for treatment

NEW CONCEPTS FOR THE TREATMENT OF ALLERGIC RHINITIS AND ASTHMA

PRESENTATION BY SENIOR SCIENTIST JENS BRIMNES, MANAGER, ALK-ABELLÓ COPENHAGEN, DEPARTMENT OF IMMUNOLOGY

Allergic rhinitis and asthma represent a major worldwide health problem. These diseases have been modelled extensively in small rodents in order to gain a better understanding of the mechanisms leading to the development of pulmonary inflammation and airway hyper reactivity. Furthermore, animal models of allergic rhinitis and asthma have been used to evaluate new concepts for the treatment of these diseases. At ALK, we have developed mouse models for rhinitis and asthma that are specific for disease-relevant allergens such as house dust mites and timothy grass pollens rather than model proteins such as ovalbumin. A recent focus in the development of these models has been to use the physiological relevant routes of sensitization and challenge. The models have been applied to evaluate the effect of sublingual immunotherapy as a treatment of respiratory allergy, and we have investigated the underlying immunological mechanisms of this treatment.

DEVELOPING NEW ADJUVANTS BASED ON CATIONIC LIPOSEMES

PRESENTATION BY SENIOR SCIENTIST DENNIS CHRISTENSEN, STATENS SERUM INSTITUT

Adjuvants can be used to direct the immune response, which is relevant for vaccines against infections, cancer, etc. Lately adjuvants have also been implicated in preventing unwanted immune responses, such as responses involved in allergy and autoimmune diseases. The SSI vaccine adjuvant program was launched over 15 years ago and has, so far, placed two adjuvants in clinical development. The adjuvant platform is based on cationic liposomes. The first generation adjuvant CAF01 has been used with good results in four finalized and one ongoing phase 1 clinical trials, so far, and our second generation adjuvant CAF09b is entering into clinical trials later this year. In this talk, I will describe how we design adjuvants to induce different types of immune responses by modifying immunostimulator combinations, physical properties of the delivery system and/or vaccine administration routes.

PROGRAMME

14:00 – 14:05 Welcome to the SSI

14:05 – 14:40 NEW CONCEPTS FOR TREATMENT OF ALLERGIC RHINITIS AND ASTHMA
Jens Brimnes, ALK

14:55 – 15:20 DEVELOPING NEW ADJUVANTS BASED ON CATIONIC LIPOSEMES
Dennis Christensen, SSI

WHERE

Statens Serum Institut, Artillerivej 5, 2300 København S
Foredragssalen, building 43, room 219

Please go to the reception upon arrival for sign-up and ID-card.

WHEN

Monday, 22 May 2017 at 14:00-15:30.

REGISTRATION

It is not necessary to register for this event. Attendance is free of charge.

If you think that anyone else in your network could be interested in attending this seminar, please feel free to forward this invitation (with cc to: paho@ssi.dk)